SI-BONE (SIBN) Q2 FY26 earnings call

SI-BONE delivered robust Q2 FY26 results, driven by broad-based procedural demand and strong physician engagement, leading to significant revenue growth and improved profitability. The company is strategically investing in R&D and commercial capacity ahead of multiple product launches, including a third breakthrough device, and anticipates further tailwinds from favorable reimbursement changes for Granite and SI joint procedures.